RT Journal Article
T1 Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders.
A1 Pérez de la Mora, Miguel
A1 Borroto-Escuela, Dasiel O
A1 Crespo-Ramírez, Minerva
A1 Rejón-Orantes, José Del Carmen
A1 Palacios-Lagunas, Daniel Alejandro
A1 Martínez-Mata, Magda K
A1 Sánchez-Luna, Daniela
A1 Tesoro-Cruz, Emiliano
A1 Fuxe, Kjell
K1 G-protein coupled receptors
K1 anxiety
K1 depression
K1 heteromeric complexes
K1 receptor oligomerization
K1 receptor-receptor interactions
AB Among mental diseases, major depressive disorder (MDD) and anxiety deserve a special place due to their high prevalence and their negative impact both on society and patients suffering from these disorders. Consequently, the development of novel strategies designed to treat them quickly and efficiently, without or at least having limited side effects, is considered a highly important goal. Growing evidence indicates that emerging properties are developed on recognition, trafficking, and signaling of G-protein coupled receptors (GPCRs) upon their heteromerization with other types of GPCRs, receptor tyrosine kinases, and ionotropic receptors such as N-methyl-D-aspartate (NMDA) receptors. Therefore, to develop new treatments for MDD and anxiety, it will be important to identify the most vulnerable heteroreceptor complexes involved in MDD and anxiety. This review focuses on how GPCRs, especially serotonin, dopamine, galanin, and opioid heteroreceptor complexes, modulate synaptic and volume transmission in the limbic networks of the brain. We attempt to provide information showing how these emerging concepts can contribute to finding new ways to treat both MDD and anxiety disorders.
YR 2022
FD 2022-06-02
LK http://hdl.handle.net/10668/20932
UL http://hdl.handle.net/10668/20932
LA en
DS RISalud
RD Apr 19, 2025